Scatec ASA
Invitation to presentation of Scatec ASA’s fourth quarter results 2025
Invitation to presentation of Scatec ASA’s fourth quarter results 2025
Oslo, 16 January 2026: Scatec ASA will release its fourth quarter results on Friday 30 January 2026 at 07:00 CET.
A presentation followed by a Q&A session will be held on the same day at 09:00 CET at Scatec’s headquarters at Skøyen Atrium III (1st floor), Askekroken 11, 0277 Oslo. The presentation and the Q&A session can be followed through a live webcast: Scatec webcast Q4 2025.
For further information, please contact:
For analysts and investors:
Andreas Austrell, SVP IR
andreas.austrell@scatec.com
+47 974 38 686
For media:
Meera Bhatia, SVP External Affairs & Communications
meera.bhatia@scatec.com
+47 468 44 959
About Scatec
Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 6.2 GW in operation and under construction across five continents today. We are committed to grow our renewable energy capacity, delivered by our passionate employees and partners who are driven by a common vision of ‘Improving our Future’. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘SCATC’. To learn more, visit www.scatec.com or connect with us on LinkedIn.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S16.1.2026 19:30:00 CET | Press release
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharma AG16.1.2026 18:00:00 CET | Press release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Aspo Plc16.1.2026 17:30:00 CET | Press release
Aspo Plc: Share repurchase 16.1.2026
Yacht Club de Monaco16.1.2026 16:53:08 CET | Press release
Next-generation sailors take centre stage at the Monaco Optimist Team Race
Nilfisk Holding A/S16.1.2026 16:25:51 CET | Press release
Court ruling in insurance dispute related to US distribution center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom